董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas W. Burns | 男 | Director | 64 | 未披露 | 未持股 | 2025-11-03 |
| Glendon E. French | 男 | President, Chief Executive Officer and Director | 63 | 112.25万美元 | 未持股 | 2025-11-03 |
| Richard Ferrari | 男 | Director | 71 | 未披露 | 未持股 | 2025-11-03 |
| Daniel Florin | 男 | Director | 61 | 2.60万美元 | 未持股 | 2025-11-03 |
| Georgia Garinois Melenikiotou | 女 | Director | 65 | 未披露 | 未持股 | 2025-11-03 |
| Tiffany Sullivan | 女 | Director | 50 | 未披露 | 未持股 | 2025-11-03 |
| Dana G. Mead, Jr. | 男 | Chairman | 66 | 2.85万美元 | 未持股 | 2025-11-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Derrick Sung | 男 | Chief Operating Officer and Chief Financial Officer | 52 | 42.89万美元 | 未持股 | 2025-11-03 |
| Glendon E. French | 男 | President, Chief Executive Officer and Director | 63 | 112.25万美元 | 未持股 | 2025-11-03 |
| Geoffrey Beran Rose | 男 | Chief Commercial Officer | 52 | 47.33万美元 | 未持股 | 2025-11-03 |
| David Lehman | 男 | General Counsel | 64 | 未披露 | 未持股 | 2025-11-03 |
董事简历
中英对照 | 中文 | 英文- Thomas W. Burns
-
Thomas W. Burns自2020年9月起担任Pulmonx公司董事会成员。自2002年3月以来，Burns先生一直担任医疗技术和制药公司Glaukos Corporation的总裁、首席执行官和董事会成员。从2009年10月至2015年6月，Burns先生担任医疗技术公司DOSE Medical Corporation的董事会成员和主席。2010年3月至2015年6月，Burns先生担任DOSE医疗公司首席执行官兼总裁。2018年7月至2019年8月，Burns先生在Avedro，Inc.被Glaukos收购之前担任该公司董事会成员。Burns先生拥有耶鲁大学的学士学位。
Thomas W. Burns,has served as Chairman of the Board and Chief Executive Officer of Glaukos Corporation, a medical technology and pharmaceutical company ("Glaukos"). Mr. Burns has served as Chief Executive Officer and a member of the board of directors of Glaukos since March 2002, and additionally served as President from March 2002 to March 2022. From October 2009 until June 2015, Mr. Burns served as a member and the Chairman of the board of directors of DOSE Medical Corporation, a medical technology company. From March 2010 until June 2015, Mr. Burns served as DOSE Medical Corporation's Chief Executive Officer and President. From July 2018 until August 2019, Mr. Burns served on the board of directors of Avedro, Inc., prior to its acquisition by Glaukos. Mr. Burns holds a B.A. from Yale University. - Thomas W. Burns自2020年9月起担任Pulmonx公司董事会成员。自2002年3月以来，Burns先生一直担任医疗技术和制药公司Glaukos Corporation的总裁、首席执行官和董事会成员。从2009年10月至2015年6月，Burns先生担任医疗技术公司DOSE Medical Corporation的董事会成员和主席。2010年3月至2015年6月，Burns先生担任DOSE医疗公司首席执行官兼总裁。2018年7月至2019年8月，Burns先生在Avedro，Inc.被Glaukos收购之前担任该公司董事会成员。Burns先生拥有耶鲁大学的学士学位。
- Thomas W. Burns,has served as Chairman of the Board and Chief Executive Officer of Glaukos Corporation, a medical technology and pharmaceutical company ("Glaukos"). Mr. Burns has served as Chief Executive Officer and a member of the board of directors of Glaukos since March 2002, and additionally served as President from March 2002 to March 2022. From October 2009 until June 2015, Mr. Burns served as a member and the Chairman of the board of directors of DOSE Medical Corporation, a medical technology company. From March 2010 until June 2015, Mr. Burns served as DOSE Medical Corporation's Chief Executive Officer and President. From July 2018 until August 2019, Mr. Burns served on the board of directors of Avedro, Inc., prior to its acquisition by Glaukos. Mr. Burns holds a B.A. from Yale University.
- Glendon E. French
-
Glendon E.French自2014年12月起担任公司总裁、首席执行官和董事会成员。French从2014年1月到2014年11月担任Apnicure（一家医疗设备公司）首席执行官和董事。2010年10月至2012年12月，French先生担任医疗器械公司波士顿科学国际有限公司的肺内窥镜总裁。French从2003年12月到2010年10月担任Asthmatx，Inc.（一家医疗设备公司）总裁和首席执行官以及董事。French先生担任医疗器械公司Levita Magnetics International Corp.的董事会执行主席。French先生拥有达特茅斯学院（Dartmouth College）历史学学士学位和宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）工商管理硕士学位。
Glendon E. French,served as Chief Executive Officer and as a director of ApniCure, a medical device company. From October 2010 to December 2012, Mr. French served as President, Pulmonary Endoscopy for Boston Scientific Corporation, a medical device company. From December 2003 to October 2010, Mr. French served as President and Chief Executive Officer and as a director of Asthmatx, Inc., a medical device company. In addition to serving on Pulmonx Corporation Board of Directors, Mr. French has served on the board of directors of Myka Labs, Inc. since July 2024, the board of directors of CoLabs, Inc. since January 2025, and the board of directors of EDAP TMS S.A. since February 2025. Mr. French served as the Executive Chairman of the board of directors of Levita Magnetics International Corp., a medical device company, from August 2013 to January 2022. Mr. French holds a B.A. in History from Dartmouth College and an M.B.A. from the Wharton School at the University of Pennsylvania. - Glendon E.French自2014年12月起担任公司总裁、首席执行官和董事会成员。French从2014年1月到2014年11月担任Apnicure（一家医疗设备公司）首席执行官和董事。2010年10月至2012年12月，French先生担任医疗器械公司波士顿科学国际有限公司的肺内窥镜总裁。French从2003年12月到2010年10月担任Asthmatx，Inc.（一家医疗设备公司）总裁和首席执行官以及董事。French先生担任医疗器械公司Levita Magnetics International Corp.的董事会执行主席。French先生拥有达特茅斯学院（Dartmouth College）历史学学士学位和宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）工商管理硕士学位。
- Glendon E. French,served as Chief Executive Officer and as a director of ApniCure, a medical device company. From October 2010 to December 2012, Mr. French served as President, Pulmonary Endoscopy for Boston Scientific Corporation, a medical device company. From December 2003 to October 2010, Mr. French served as President and Chief Executive Officer and as a director of Asthmatx, Inc., a medical device company. In addition to serving on Pulmonx Corporation Board of Directors, Mr. French has served on the board of directors of Myka Labs, Inc. since July 2024, the board of directors of CoLabs, Inc. since January 2025, and the board of directors of EDAP TMS S.A. since February 2025. Mr. French served as the Executive Chairman of the board of directors of Levita Magnetics International Corp., a medical device company, from August 2013 to January 2022. Mr. French holds a B.A. in History from Dartmouth College and an M.B.A. from the Wharton School at the University of Pennsylvania.
- Richard Ferrari
-
Richard Ferrari，2007年2月起，担任本公司董事。Ferrari先生是De Novo Ventures（一家致力于医疗设备和生物技术的梦百合投资公司）的联合创始人和董事总经理。Ferrari先生还担任斯坦福生物设计新兴企业家论坛（Stanford Biodesign Emergencers Forum）的教员，以及斯坦福库尔特转化医学基金会（Stanford Coulter Foundation for Translational Medicine）的董事会成员。Ferrari从1995年10月到1999年5月联合创立CardioThoracic Systems，Inc.（一家手术医疗技术和设备公司）并担任首席执行官。Ferrari从1990年1月到1995年6月担任Cardiovascular Imaging Systems（超声成像开发商）首席执行官。Ferrari先生拥有Ashland University的B.S.和University of South Florida的M.B.A.。
Richard Ferrari,is the Co-Founder of De Novo Ventures, a healthcare investment firm dedicated to medical devices and bio-technology, and has served as a Managing Director since 2000. Mr. Ferrari also serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum. From October 1995 to May 1999, Mr. Ferrari co-founded and served as the Chief Executive Officer of CardioThoracic Systems, Inc., a manufacturer of products and systems for minimally invasive cardiac surgery. From January 1990 to June 1995, Mr. Ferrari served as the CEO of Cardiovascular Imaging Systems, a developer of ultrasound imaging. Mr. Ferrari has served on the board of directors of HeartBeam, Inc. since December 2019 and as Executive Chairman since June 2021. Mr. Ferrari also serves as the Executive Chairman and a member of the board of directors of Tenon Medical, Inc. Mr. Ferrari is Executive Chairman of the Board for Retriever Medical Inc.; Vice Chairman of the Board for Advanced Bifurcation Systems Inc.; and a board member of several other private medical device companies. Mr. Ferrari holds a B.S. from Ashland University and an M.B.A. from the University of South Florida. - Richard Ferrari，2007年2月起，担任本公司董事。Ferrari先生是De Novo Ventures（一家致力于医疗设备和生物技术的梦百合投资公司）的联合创始人和董事总经理。Ferrari先生还担任斯坦福生物设计新兴企业家论坛（Stanford Biodesign Emergencers Forum）的教员，以及斯坦福库尔特转化医学基金会（Stanford Coulter Foundation for Translational Medicine）的董事会成员。Ferrari从1995年10月到1999年5月联合创立CardioThoracic Systems，Inc.（一家手术医疗技术和设备公司）并担任首席执行官。Ferrari从1990年1月到1995年6月担任Cardiovascular Imaging Systems（超声成像开发商）首席执行官。Ferrari先生拥有Ashland University的B.S.和University of South Florida的M.B.A.。
- Richard Ferrari,is the Co-Founder of De Novo Ventures, a healthcare investment firm dedicated to medical devices and bio-technology, and has served as a Managing Director since 2000. Mr. Ferrari also serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum. From October 1995 to May 1999, Mr. Ferrari co-founded and served as the Chief Executive Officer of CardioThoracic Systems, Inc., a manufacturer of products and systems for minimally invasive cardiac surgery. From January 1990 to June 1995, Mr. Ferrari served as the CEO of Cardiovascular Imaging Systems, a developer of ultrasound imaging. Mr. Ferrari has served on the board of directors of HeartBeam, Inc. since December 2019 and as Executive Chairman since June 2021. Mr. Ferrari also serves as the Executive Chairman and a member of the board of directors of Tenon Medical, Inc. Mr. Ferrari is Executive Chairman of the Board for Retriever Medical Inc.; Vice Chairman of the Board for Advanced Bifurcation Systems Inc.; and a board member of several other private medical device companies. Mr. Ferrari holds a B.S. from Ashland University and an M.B.A. from the University of South Florida.
- Daniel Florin
-
Daniel Florin自2020年1月起担任我们的董事会成员。2019年7月至2020年3月，Florin先生担任医疗器械公司Zimmer Biomet Holdings Inc.的执行Vice President。2015年6月至2019年7月，Florin先生担任Zimmer Biomet&；8217；S的执行Vice President和首席财务官。从2017年7月至2017年12月，Florin先生担任Zimmer Biomet&8217；的临时首席执行官。2007年6月至2015年6月，在Biomet与Zimmer合并之前，Florin先生担任Biomet，Inc.的高级副总裁兼首席财务官。2001年1月至2007年5月，Florin先生担任波士顿科学国际有限公司的Vice President和公司财务总监。Florin先生自2019年12月起担任AtriCure，Inc.董事会成员。Florin先生拥有圣母大学（University of Notre Dame）的会计学学士学位和波士顿大学（Boston University）的工商管理硕士学位。
Daniel Florin,has served as Chief Executive Officer of Catholic Charities Diocese of Fort Wayne-South Bend, Indiana since February 2022. From July 2019 to March 2020, Mr. Florin served as Executive Vice President of Zimmer Biomet Holdings Inc., a medical device company. From June 2015 to July 2019, Mr. Florin served as Zimmer Biomet's Executive Vice President and Chief Financial Officer. From July 2017 to December 2017, Mr. Florin served as Zimmer Biomet's Interim Chief Executive Officer. From June 2007 to June 2015, Mr. Florin served as Senior Vice President and Chief Financial Officer at Biomet, Inc. (prior to Biomet's merger with Zimmer). From January 2001 to May 2007, Mr. Florin served as Vice President and Corporate Controller of Boston Scientific Corporation. Mr. Florin served as a board member at AtriCure, Inc. from December 2019 to May 2022. Mr. Florin holds a B.A. with a concentration in Accounting from the University of Notre Dame and an M.B.A. from Boston University. - Daniel Florin自2020年1月起担任我们的董事会成员。2019年7月至2020年3月，Florin先生担任医疗器械公司Zimmer Biomet Holdings Inc.的执行Vice President。2015年6月至2019年7月，Florin先生担任Zimmer Biomet&；8217；S的执行Vice President和首席财务官。从2017年7月至2017年12月，Florin先生担任Zimmer Biomet&8217；的临时首席执行官。2007年6月至2015年6月，在Biomet与Zimmer合并之前，Florin先生担任Biomet，Inc.的高级副总裁兼首席财务官。2001年1月至2007年5月，Florin先生担任波士顿科学国际有限公司的Vice President和公司财务总监。Florin先生自2019年12月起担任AtriCure，Inc.董事会成员。Florin先生拥有圣母大学（University of Notre Dame）的会计学学士学位和波士顿大学（Boston University）的工商管理硕士学位。
- Daniel Florin,has served as Chief Executive Officer of Catholic Charities Diocese of Fort Wayne-South Bend, Indiana since February 2022. From July 2019 to March 2020, Mr. Florin served as Executive Vice President of Zimmer Biomet Holdings Inc., a medical device company. From June 2015 to July 2019, Mr. Florin served as Zimmer Biomet's Executive Vice President and Chief Financial Officer. From July 2017 to December 2017, Mr. Florin served as Zimmer Biomet's Interim Chief Executive Officer. From June 2007 to June 2015, Mr. Florin served as Senior Vice President and Chief Financial Officer at Biomet, Inc. (prior to Biomet's merger with Zimmer). From January 2001 to May 2007, Mr. Florin served as Vice President and Corporate Controller of Boston Scientific Corporation. Mr. Florin served as a board member at AtriCure, Inc. from December 2019 to May 2022. Mr. Florin holds a B.A. with a concentration in Accounting from the University of Notre Dame and an M.B.A. from Boston University.
- Georgia Garinois Melenikiotou
-
Georgia Garinois Melenikiotou自2020年7月起担任我们的董事会成员。Garinois-Melenikiotou女士曾于2015年1月至2020年7月担任全球美容产品公司EST&233；E Lauder Companies&8221；的企业营销部执行Vice President，并于2010年至2014年12月担任ELC&8217；S的企业营销部高级副总裁，。在加入ELC之前，Garinois-Melenikiotou在强生公司拥有27年的职业生涯，该公司是一家医疗器械、医药产品和包装消费品的全球制造商，包括几个高级领导职位，最近的职位是从2007年到2010年担任美容全球业务部门战略和新增长部总裁，在此之前，从2006年到2007年，担任EAME美容护理总裁。除了担任我们的董事会成员外，Garinois-Melenikiotou女士自2015年起担任西班牙制药公司Almirall，S.A.的董事会成员，自2020年9月起担任医疗技术公司Pulmonx Corporation的董事会成员。Garinois-Melenikiotou女士拥有雅典国立技术大学工程学学士学位和硕士学位，以及M.I.T.斯隆管理学院工商管理硕士学位。
Georgia Garinois Melenikiotou,served as Executive Vice President, Corporate Marketing at The Estée Lauder Companies, a global beauty products company, from January 2015 to July 2020, and as Senior Vice President, Corporate Marketing from April 2010 through December 2014. Prior to The Estée Lauder Companies, Ms. Garinois-Melenikiotou spent 27-years at Johnson & Johnson, a global manufacturer of medical devices, pharmaceutical products and consumer packaged goods, including in several senior leadership positions, most recently as President, Beauty Global Business Unit Strategy and New Growth from 2007 to 2010 and, from 2006 to 2007, as President, Beauty Care, EAME. Ms. Garinois-Melenikiotou currently serves on the boards of directors of Douglas Group, a European beauty products retailer, since March 2024, and Inspire Medical Systems, a medical device company, since July 2020. She has also served on the board of directors of Almirall, S.A. from June 2016 to June 2022 and the board of directors of Natura & Co Holding S.A. from April 2021 to September 2024. Additionally, Ms. Garinois-Melenikiotou serves on the board of directors of the Sloan School of Management at M.I.T. Ms. Garinois-Melenikiotou holds a B.S. and an M.S. in Engineering from the National Technical University of Athens and an M.B.A. from the Sloan School of Management at M.I.T. - Georgia Garinois Melenikiotou自2020年7月起担任我们的董事会成员。Garinois-Melenikiotou女士曾于2015年1月至2020年7月担任全球美容产品公司EST&233；E Lauder Companies&8221；的企业营销部执行Vice President，并于2010年至2014年12月担任ELC&8217；S的企业营销部高级副总裁，。在加入ELC之前，Garinois-Melenikiotou在强生公司拥有27年的职业生涯，该公司是一家医疗器械、医药产品和包装消费品的全球制造商，包括几个高级领导职位，最近的职位是从2007年到2010年担任美容全球业务部门战略和新增长部总裁，在此之前，从2006年到2007年，担任EAME美容护理总裁。除了担任我们的董事会成员外，Garinois-Melenikiotou女士自2015年起担任西班牙制药公司Almirall，S.A.的董事会成员，自2020年9月起担任医疗技术公司Pulmonx Corporation的董事会成员。Garinois-Melenikiotou女士拥有雅典国立技术大学工程学学士学位和硕士学位，以及M.I.T.斯隆管理学院工商管理硕士学位。
- Georgia Garinois Melenikiotou,served as Executive Vice President, Corporate Marketing at The Estée Lauder Companies, a global beauty products company, from January 2015 to July 2020, and as Senior Vice President, Corporate Marketing from April 2010 through December 2014. Prior to The Estée Lauder Companies, Ms. Garinois-Melenikiotou spent 27-years at Johnson & Johnson, a global manufacturer of medical devices, pharmaceutical products and consumer packaged goods, including in several senior leadership positions, most recently as President, Beauty Global Business Unit Strategy and New Growth from 2007 to 2010 and, from 2006 to 2007, as President, Beauty Care, EAME. Ms. Garinois-Melenikiotou currently serves on the boards of directors of Douglas Group, a European beauty products retailer, since March 2024, and Inspire Medical Systems, a medical device company, since July 2020. She has also served on the board of directors of Almirall, S.A. from June 2016 to June 2022 and the board of directors of Natura & Co Holding S.A. from April 2021 to September 2024. Additionally, Ms. Garinois-Melenikiotou serves on the board of directors of the Sloan School of Management at M.I.T. Ms. Garinois-Melenikiotou holds a B.S. and an M.S. in Engineering from the National Technical University of Athens and an M.B.A. from the Sloan School of Management at M.I.T.
- Tiffany Sullivan
-
Tiffany Sullivan，曾担任纽约长老会医院医师服务高级副总裁兼首席运营官。Sullivan女士此前曾于2018年1月至2020年10月在马里兰大学首都地区健康学院担任临床整合和门诊服务高级副总裁，并于2016年1月至2017年12月担任社区和Population Health副总裁。沙利文女士拥有南卡罗来纳大学阿诺德公共卫生学院硕士学位和哥伦比亚学院生物学学士学位。Sullivan女士获得了许多荣誉和奖项，包括Foster G. McGaw社区服务卓越奖和国会议员James E. Clyburn公共卫生和健康差异社区领导奖。
Tiffany Sullivan,has served as the Senior Vice President and Chief Operating Officer, Physician Services at New York-Presbyterian Hospital. Ms. Sullivan previously served as the Senior Vice President, Clinical Integration and Ambulatory Services at University of Maryland Capital Region Health from January 2018 through October 2020, and as the Vice President, Community and Population Health from January 2016 through December 2017. Ms. Sullivan holds an M.P.H. from the University of South Carolina, Arnold School of Public Health, and a B.A. in Biology from Columbia College. Ms. Sullivan has received many honors and awards including the Foster G. McGaw Prize for Excellence in Community Service and the Congressman James E. Clyburn Public Health and Health Disparities Community Leadership Award. - Tiffany Sullivan，曾担任纽约长老会医院医师服务高级副总裁兼首席运营官。Sullivan女士此前曾于2018年1月至2020年10月在马里兰大学首都地区健康学院担任临床整合和门诊服务高级副总裁，并于2016年1月至2017年12月担任社区和Population Health副总裁。沙利文女士拥有南卡罗来纳大学阿诺德公共卫生学院硕士学位和哥伦比亚学院生物学学士学位。Sullivan女士获得了许多荣誉和奖项，包括Foster G. McGaw社区服务卓越奖和国会议员James E. Clyburn公共卫生和健康差异社区领导奖。
- Tiffany Sullivan,has served as the Senior Vice President and Chief Operating Officer, Physician Services at New York-Presbyterian Hospital. Ms. Sullivan previously served as the Senior Vice President, Clinical Integration and Ambulatory Services at University of Maryland Capital Region Health from January 2018 through October 2020, and as the Vice President, Community and Population Health from January 2016 through December 2017. Ms. Sullivan holds an M.P.H. from the University of South Carolina, Arnold School of Public Health, and a B.A. in Biology from Columbia College. Ms. Sullivan has received many honors and awards including the Foster G. McGaw Prize for Excellence in Community Service and the Congressman James E. Clyburn Public Health and Health Disparities Community Leadership Award.
- Dana G. Mead, Jr.
-
Dana G. Mead, Jr.，自2008年7月起担任董事会成员。Mead先生于2019年5月至2021年2月担任HeartFlow，Inc.的首席执行官兼总裁，HeartFlow，Inc.是一家改变心脏病诊断和治疗方式的数字健康公司。2016年至2019年5月，Mead先生担任Beaver-Visitec International，Inc.的首席执行官兼总裁，Beaver-Visitec International，Inc.是一家外科手术设备开发商和制造商。从2005年到2016年，Mead先生在风险投资公司Kleiner Perkins Caufield & Byers担任合伙人。除了在董事会任职外，Mead先生自2015年6月起担任医疗技术公司Intersect ENT，Inc.的董事会成员，自2008年起担任Pulmonx Corporation的董事会成员。2011年5月至2016年12月，Mead先生在远程健康公司Teladoc, Inc.的董事会任职。Mead先生拥有拉法叶学院的学士学位和南加州大学的工商管理硕士学位。
Dana G. Mead, Jr.,served as the Chief Executive Officer, President and director of HeartFlow, Inc., a medical technology company. From November 2016 to May 2019, Mr. Mead served as President and Chief Executive Officer of Beaver-Visitec International, Inc., a surgical device developer and manufacturer. From June 2005 to November 2016, Mr. Mead served as a partner at Kleiner Perkins Caufield & Byers, a venture capital investment firm. In addition to serving on Pulmonx Corporation Board of Directors, Mr. Mead has served on the board of directors of Inari Medical, Inc. since October 2021 and the board of directors of Inspire Medical Systems since July 2008, where he serves on its audit committee. Mr. Mead also served on the board of directors of Inari Medical, Inc. from October 2021 until its sale to Stryker in February 2025 and Intersect ENT, Inc. from January 2006 until its sale to Medtronic, Inc. in May 2022. Mr. Mead holds a B.A. from Lafayette College and an M.B.A. from the University of Southern California. - Dana G. Mead, Jr.，自2008年7月起担任董事会成员。Mead先生于2019年5月至2021年2月担任HeartFlow，Inc.的首席执行官兼总裁，HeartFlow，Inc.是一家改变心脏病诊断和治疗方式的数字健康公司。2016年至2019年5月，Mead先生担任Beaver-Visitec International，Inc.的首席执行官兼总裁，Beaver-Visitec International，Inc.是一家外科手术设备开发商和制造商。从2005年到2016年，Mead先生在风险投资公司Kleiner Perkins Caufield & Byers担任合伙人。除了在董事会任职外，Mead先生自2015年6月起担任医疗技术公司Intersect ENT，Inc.的董事会成员，自2008年起担任Pulmonx Corporation的董事会成员。2011年5月至2016年12月，Mead先生在远程健康公司Teladoc, Inc.的董事会任职。Mead先生拥有拉法叶学院的学士学位和南加州大学的工商管理硕士学位。
- Dana G. Mead, Jr.,served as the Chief Executive Officer, President and director of HeartFlow, Inc., a medical technology company. From November 2016 to May 2019, Mr. Mead served as President and Chief Executive Officer of Beaver-Visitec International, Inc., a surgical device developer and manufacturer. From June 2005 to November 2016, Mr. Mead served as a partner at Kleiner Perkins Caufield & Byers, a venture capital investment firm. In addition to serving on Pulmonx Corporation Board of Directors, Mr. Mead has served on the board of directors of Inari Medical, Inc. since October 2021 and the board of directors of Inspire Medical Systems since July 2008, where he serves on its audit committee. Mr. Mead also served on the board of directors of Inari Medical, Inc. from October 2021 until its sale to Stryker in February 2025 and Intersect ENT, Inc. from January 2006 until its sale to Medtronic, Inc. in May 2022. Mr. Mead holds a B.A. from Lafayette College and an M.B.A. from the University of Southern California.
高管简历
中英对照 | 中文 | 英文- Derrick Sung
Derrick Sung自2019年5月起担任Pulmonx Corporation首席财务官职务。2015年5月至2019年5月，Sung博士在数字医疗保健和医疗技术公司iRhythm Technologies, Inc.担任战略与企业发展执行副总裁。2008年2月至2015年4月，Sung博士担任AllianceBernstein有限公司的子公司Sanford C. Bernstein & Co.，LLC医疗器械部门的高级股票研究分析师。2004年至2008年，他担任Boston Scientific Corporation神经调节部门的市场和业务发展总监。2000年至2004年，Sung博士在商业咨询公司Boston Consulting Group担任管理顾问。Sung博士拥有圣迭戈大学生物工程博士学位、圣迭戈州立大学工商管理硕士学位和斯坦福大学机械工程学士学位。
Derrick Sung,has served as Chief Financial Officer of Aerin Medical, Inc., a medical device company serving the Ear, Nose, and Throat medical specialty. From May 2019 to October 2023, Dr. Sung served as the Company's Chief Financial Officer. From May 2015 to May 2019, Dr. Sung served as the Executive Vice President of Strategy and Corporate Development for iRhythm Technologies, Inc., a digital healthcare and medical technology company. From February 2008 to April 2015, Dr. Sung was the senior equity research analyst covering the medical devices sector for Sanford C. Bernstein & Co., LLC, a subsidiary of AllianceBernstein L.P. From 2004 to 2008, he served as Director of Marketing and Business Development in the Neuromodulation division of Boston Scientific Corporation. From 2000 to 2004, Dr. Sung was a management consultant at The Boston Consulting Group, a business consulting firm. Dr. Sung holds a Ph.D. in Bioengineering from The University of California, San Diego, an M.B.A. from San Diego State University and a B.S. in Mechanical Engineering from Stanford University. Dr. Sung has served on the board of directors of Sensydia Corporation since August 2018.- Derrick Sung自2019年5月起担任Pulmonx Corporation首席财务官职务。2015年5月至2019年5月，Sung博士在数字医疗保健和医疗技术公司iRhythm Technologies, Inc.担任战略与企业发展执行副总裁。2008年2月至2015年4月，Sung博士担任AllianceBernstein有限公司的子公司Sanford C. Bernstein & Co.，LLC医疗器械部门的高级股票研究分析师。2004年至2008年，他担任Boston Scientific Corporation神经调节部门的市场和业务发展总监。2000年至2004年，Sung博士在商业咨询公司Boston Consulting Group担任管理顾问。Sung博士拥有圣迭戈大学生物工程博士学位、圣迭戈州立大学工商管理硕士学位和斯坦福大学机械工程学士学位。
- Derrick Sung,has served as Chief Financial Officer of Aerin Medical, Inc., a medical device company serving the Ear, Nose, and Throat medical specialty. From May 2019 to October 2023, Dr. Sung served as the Company's Chief Financial Officer. From May 2015 to May 2019, Dr. Sung served as the Executive Vice President of Strategy and Corporate Development for iRhythm Technologies, Inc., a digital healthcare and medical technology company. From February 2008 to April 2015, Dr. Sung was the senior equity research analyst covering the medical devices sector for Sanford C. Bernstein & Co., LLC, a subsidiary of AllianceBernstein L.P. From 2004 to 2008, he served as Director of Marketing and Business Development in the Neuromodulation division of Boston Scientific Corporation. From 2000 to 2004, Dr. Sung was a management consultant at The Boston Consulting Group, a business consulting firm. Dr. Sung holds a Ph.D. in Bioengineering from The University of California, San Diego, an M.B.A. from San Diego State University and a B.S. in Mechanical Engineering from Stanford University. Dr. Sung has served on the board of directors of Sensydia Corporation since August 2018.
- Glendon E. French
Glendon E.French自2014年12月起担任公司总裁、首席执行官和董事会成员。French从2014年1月到2014年11月担任Apnicure（一家医疗设备公司）首席执行官和董事。2010年10月至2012年12月，French先生担任医疗器械公司波士顿科学国际有限公司的肺内窥镜总裁。French从2003年12月到2010年10月担任Asthmatx，Inc.（一家医疗设备公司）总裁和首席执行官以及董事。French先生担任医疗器械公司Levita Magnetics International Corp.的董事会执行主席。French先生拥有达特茅斯学院（Dartmouth College）历史学学士学位和宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）工商管理硕士学位。
Glendon E. French,served as Chief Executive Officer and as a director of ApniCure, a medical device company. From October 2010 to December 2012, Mr. French served as President, Pulmonary Endoscopy for Boston Scientific Corporation, a medical device company. From December 2003 to October 2010, Mr. French served as President and Chief Executive Officer and as a director of Asthmatx, Inc., a medical device company. In addition to serving on Pulmonx Corporation Board of Directors, Mr. French has served on the board of directors of Myka Labs, Inc. since July 2024, the board of directors of CoLabs, Inc. since January 2025, and the board of directors of EDAP TMS S.A. since February 2025. Mr. French served as the Executive Chairman of the board of directors of Levita Magnetics International Corp., a medical device company, from August 2013 to January 2022. Mr. French holds a B.A. in History from Dartmouth College and an M.B.A. from the Wharton School at the University of Pennsylvania.- Glendon E.French自2014年12月起担任公司总裁、首席执行官和董事会成员。French从2014年1月到2014年11月担任Apnicure（一家医疗设备公司）首席执行官和董事。2010年10月至2012年12月，French先生担任医疗器械公司波士顿科学国际有限公司的肺内窥镜总裁。French从2003年12月到2010年10月担任Asthmatx，Inc.（一家医疗设备公司）总裁和首席执行官以及董事。French先生担任医疗器械公司Levita Magnetics International Corp.的董事会执行主席。French先生拥有达特茅斯学院（Dartmouth College）历史学学士学位和宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）工商管理硕士学位。
- Glendon E. French,served as Chief Executive Officer and as a director of ApniCure, a medical device company. From October 2010 to December 2012, Mr. French served as President, Pulmonary Endoscopy for Boston Scientific Corporation, a medical device company. From December 2003 to October 2010, Mr. French served as President and Chief Executive Officer and as a director of Asthmatx, Inc., a medical device company. In addition to serving on Pulmonx Corporation Board of Directors, Mr. French has served on the board of directors of Myka Labs, Inc. since July 2024, the board of directors of CoLabs, Inc. since January 2025, and the board of directors of EDAP TMS S.A. since February 2025. Mr. French served as the Executive Chairman of the board of directors of Levita Magnetics International Corp., a medical device company, from August 2013 to January 2022. Mr. French holds a B.A. in History from Dartmouth College and an M.B.A. from the Wharton School at the University of Pennsylvania.
- Geoffrey Beran Rose
Geoffrey Beran Rose自2020年1月起担任我们的首席商务官。2014年12月至2020年1月，Rose先生担任我们的Vice President，营销和业务开发。2013年8月至2014年12月，罗斯先生担任波士顿科学国际有限公司全球集团营销总监。2006年8月至2013年8月，Rose先生担任波士顿科学国际有限公司研究与开发和临床组织的战略总监。Rose先生拥有耶鲁大学（Yale University）的学士学位和麻省理工学院斯隆管理学院（MIT Sloan School of Management）的工商管理硕士学位。
Geoffrey Beran Rose,served as a Director of Marketing and Business Development in the Endoscopy Division of Boston Scientific, and from August 2006 to April 2009 , Mr. Rose served as a director in the Corporate R&D and Clinical organizations of Boston Scientific Corporation. Prior to his work at Boston Scientific, Mr. Rose worked for nine years in strategic consulting with clients in healthcare and technology. Mr. Rose holds a B.A. from Yale University and an M.B.A. from the Sloan School of Management at M.I.T.- Geoffrey Beran Rose自2020年1月起担任我们的首席商务官。2014年12月至2020年1月，Rose先生担任我们的Vice President，营销和业务开发。2013年8月至2014年12月，罗斯先生担任波士顿科学国际有限公司全球集团营销总监。2006年8月至2013年8月，Rose先生担任波士顿科学国际有限公司研究与开发和临床组织的战略总监。Rose先生拥有耶鲁大学（Yale University）的学士学位和麻省理工学院斯隆管理学院（MIT Sloan School of Management）的工商管理硕士学位。
- Geoffrey Beran Rose,served as a Director of Marketing and Business Development in the Endoscopy Division of Boston Scientific, and from August 2006 to April 2009 , Mr. Rose served as a director in the Corporate R&D and Clinical organizations of Boston Scientific Corporation. Prior to his work at Boston Scientific, Mr. Rose worked for nine years in strategic consulting with clients in healthcare and technology. Mr. Rose holds a B.A. from Yale University and an M.B.A. from the Sloan School of Management at M.I.T.
- David Lehman
David Lehman曾担任执行副总裁、总法律顾问、首席合规官和公司秘书，并于2016年2月至2019年11月担任Intersect ENT，Inc.的总法律顾问和秘书，这是一家专注于ENT的医疗技术公司。从2003年5月到2015年10月，Lehman先生在心脏病学医疗技术公司Thoratec Corporation任职，最近担任高级副总裁、总法律顾问和秘书。Lehman先生拥有加州大学圣地亚哥分校的学士学位和康奈尔大学法学院的法学博士学位。
David Lehman,served as Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary, and from February 2016 to November 2019 as General Counsel and Secretary at Intersect ENT, Inc., an ENT-focused medical technology company. From May 2003 to October 2015, Mr. Lehman was at Thoratec Corporation, a cardiology medical technology company, most recently as Senior Vice President, General Counsel and Secretary. Mr. Lehman holds a B.A. from The University of California, San Diego and a J.D. from Cornell Law School.- David Lehman曾担任执行副总裁、总法律顾问、首席合规官和公司秘书，并于2016年2月至2019年11月担任Intersect ENT，Inc.的总法律顾问和秘书，这是一家专注于ENT的医疗技术公司。从2003年5月到2015年10月，Lehman先生在心脏病学医疗技术公司Thoratec Corporation任职，最近担任高级副总裁、总法律顾问和秘书。Lehman先生拥有加州大学圣地亚哥分校的学士学位和康奈尔大学法学院的法学博士学位。
- David Lehman,served as Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary, and from February 2016 to November 2019 as General Counsel and Secretary at Intersect ENT, Inc., an ENT-focused medical technology company. From May 2003 to October 2015, Mr. Lehman was at Thoratec Corporation, a cardiology medical technology company, most recently as Senior Vice President, General Counsel and Secretary. Mr. Lehman holds a B.A. from The University of California, San Diego and a J.D. from Cornell Law School.